Risk Factors for Second Eye Involvement in Eyes with Unilateral Polypoidal Choroidal Vasculopathy.
To investigate risk factors associated with developing polypoidal choroidal vasculopathy (PCV) lesions in the unaffected fellow eye of patients with unilateral PCV.



We studied 179 patients with initial unilateral PCV who were followed up for a period of 24 months or longer to monitor for second eye involvement. All patients underwent genotyping for CFH I62V (rs800292) and ARMS2 A69S (rs10490924) using TaqMan technology.



During the follow-up period ranging from 5-180 months, 20 (11.2%) of 179 patients developed PCV in the initially unaffected fellow eye. The risk allele (T) of ARMS2 A69S was significantly more prevalent in patients with second eye involvement compared to those without PCV in the fellow eye (p = 0.0046). Cox regression analysis demonstrated that the ARMS2 A69S genotype is a risk factor for developing PCV in the fellow eye (p = 0.027, odds ratio 2.53, confidence interval 1.11-5.73). Survival analysis revealed that the fellow eye of patients with the risk-associated homozygous genotype (TT) of ARMS2 A69S was affected significantly earlier than those with other genotypes (p = 0.0177, log rank test).



Development of PCV in the unaffected fellow eye is associated with ARMS2 A69S genotype in patients with unilateral PCV.
a Departments of Ophthalmology and.
Yasushi
Y
Tateno
a Departments of Ophthalmology and.
Yoichi
Y
Sakurada
a Departments of Ophthalmology and.
Seigo
S
Yoneyama
a Departments of Ophthalmology and.
Wataru
W
Kikushima
a Departments of Ophthalmology and.
Fumihiko
F
Mabuchi
a Departments of Ophthalmology and.
Atsushi
A
Sugiyama
a Departments of Ophthalmology and.
Naohiko
N
Tanabe
b Epigenetics, Faculty of Medicine, University of Yamanashi , Yamanashi , Japan.
Takeo
T
Kubota
a Departments of Ophthalmology and.
Hiroyuki
H
Iijima
D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D020256:Choroidal Neovascularization / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics; D017242:Complement Factor H / Q000235:genetics; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D060005:Genotyping Techniques; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D011127:Polyps / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics; D011506:Proteins / Q000235:genetics*; D012189:Retrospective Studies; D012307:Risk Factors; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
C514392:ARMS2 protein, human; D020533:Angiogenesis Inhibitors; C493495:CFH protein, human; D011506:Proteins; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D017242:Complement Factor H
ARMS2 A69S; polypoidal choroidal vasculopathy; second eye involvement